SolasCure
UK - CambridgeBiotechnology
Focus: SolasCure is an early-stage UK-based biotechnology company specializing in wound care, currently advancing a Phase 2 candidate for venous leg ulcers. The company was founded in 2023 and operates as a pre-revenue biotech focused on regenerative wound healing.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About SolasCure
AI assessmentNot HiringNo open roles listed right now. Follow SolasCure to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Aurase Wound gel
Venous Leg UlcerClinical Trials (1)
NCT04956900Clinical Trial Enzyme Application Targeting Venous Leg Ulcers
Phase 2Help build intelligence for SolasCure
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.